Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

View/Open
Date
2008
Author
Jaoko Walter G.
Nakwagala, Frederick N.
Anzala, Omu
Manyonyi, Gloria Omosa
Birungi, Josephine
Nanvubya, Annet
Bashir, Farah
Bhatta, Kirana
Ogutu, Hilda
Wakasiaka, Sabina
Matu, Lucy
Waruingi, Wambui
Odada, Jane
Oyaro, Micah
Indangasi, Jackton
Ndinya-Achola, JO
Konde, Carol
Mugisha, Emmanuel
Fast, Patricia
Schmidt, Claudia
Gilmour, Jill
Tarragona, Tony
Smith, Carol
Barin, Burc
Dally, Len
Johnson, Bruce
Muluubya, Andrew
Nielsen, Leslie
Hayes, Peter
Boaz, Mark
Hughes, Peter
Hanke, Tom´aˇs
McMichael, Andrew
Bwayo, JJ
Kaleebu, Pontiano
Type
Article
Language
en
Metadata
Show full item record

Abstract
Summary: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN- ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.
URI
http://www.ncbi.nlm.nih.gov/pubmed/18440674
http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10065
Citation
Science direct
Subject
HIV—AIDS vaccine;
Collections